Blood levels of immune checkpoint antibodies and their links to inflammation, cachexia, and response in lung cancer
Official title: Inflammation, Cachexia and Therapeutic Response in Lung Cancer Treated With Immune Checkpoint Inhibitors: Exploratory Observational Study
Run by University Hospital, Tours · NCT07004868 · Data updated 2026-11-12
Test whether blood concentrations and how the body handles immune checkpoint antibodies relate to inflammation, weight loss (cachexia), and treatment response in adults with lung cancer starting immunotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | University Hospital, Tours Academic / other |
| Drugs / interventions | chemotherapy, nivolumab, pembrolizumab, atezolizumab, durvalumab |
| Locations | 1 site (Tours) |
| Status | Recruiting |
| Started | June 3, 2025 |
| Main results expected | June 2030 |
| Study ends | June 2030 |
| Registry record updated | August 11, 2025 |
| Trial ID | NCT07004868 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with any histology or stage of lung cancer who are receiving their first immune checkpoint inhibitor dose and are followed at CHRU de Tours.
✕Probably not a fit
Patients already receiving ICIs before enrollment, those not followed at CHRU de Tours, or those who refuse data processing are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center, observational project measuring blood concentrations and pharmacokinetics of various immune checkpoint inhibitor antibodies in adults with lung cancer at first administration. Investigators will collect clinical data on weight change, inflammatory markers, and treatment outcomes without changing prescribed therapy. The study will analyze relationships between antibody exposure, signs of cachexia or systemic inflammation, and subsequent clinical response or toxicity. All participants must be followed at the University Hospital (CHRU) of Tours and consent to data use.
Why it matters
Potential benefit: If successful, the findings could help tailor immunotherapy dosing and identify patients more likely to respond or to develop cachexia-related complications.
How similar studies have gone: Previous work has shown links between immune checkpoint inhibitor exposure and outcomes, but integrating detailed pharmacokinetics with inflammation and cachexia measures in lung cancer is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age greater than or equal to 18 years * Diagnosis of lung cancer, any histology, any stage * Treatment with Ab ICI, with or without chemotherapy * 1st administration of Ab ICI Exclusion Criteria: * Patient not followed at the CHRU de Tours * Person under protective supervision * Opposition to data processing
Where it's running
-
university hospital, Tours
Tours, France Recruiting
Study contacts
- Principal investigator: Marion FERREIRA, Dr — University Hospital, Tours
- Study coordinator: Marion FERREIRA, Dr
- Email: marion.ferreira@chu-tours.fr
- Phone: 0247471640
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Understanding what patients want from NSCLC treatment monitoring
Researchers are testing how patients with non-small cell lung cancer feel about and prefer monitoring their symptoms during treatment, with input from patients, caregivers, and clinicians.
-
PD-L1-targeted PET probe to map PD-L1 in solid tumors
A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.
-
Cardiorespiratory fitness after lobectomy versus sublobar resection in NSCLC
This study tests how different lung surgeries (lobectomy vs. sublobar resection) affect fitness levels after surgery in people with non-small cell lung cancer.
-
CAIX-targeted PET/CT imaging in solid tumors
Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.
-
NUT Project: Nutritional Support in Thoracic Cancer
We’ll see if providing tailored nutrition guidance and assessment helps people with advanced lung cancer during their treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.